Table 1.
Personal and health characteristics of the overall cohort, and both study groups before weighting in adults with SARS-CoV-2 infection in the omicron era at high risk of progression to severe covid-19 and eligible for treatment with molnupiravir. Values are number (percentage) unless stated otherwise
| Characteristics | Overall cohort (n=85 998) | Molnupiravir group (n=7818) | No treatment group (n=78 180) | Absolute SMD (%) |
|---|---|---|---|---|
| Mean (SD) age (years) | 67.3 (12.7) | 69.2 (12.0) | 67.1 (12.7) | 17.0 |
| Race: | ||||
| White | 65 079 (75.7) | 6216 (79.5) | 58 863 (75.3) | 10.1 |
| Black | 16 452 (19.1) | 1262 (16.1) | 15 190 (19.4) | 8.6 |
| Other | 4467 (5.2) | 340 (4.4) | 4127 (5.3) | 4.3 |
| Sex: | ||||
| Men | 77 014 (89.5) | 7129 (91.2) | 69 885 (89.4) | 6.1 |
| Women | 8984 (10.5) | 689 (8.8) | 8295 (10.6) | 6.1 |
| Smoking status: | ||||
| Never | 34 869 (40.5) | 3001 (38.4) | 31 868 (40.8) | 4.8 |
| Former | 36 167 (42.1) | 3544 (45.3) | 32 623 (41.7) | 7.3 |
| Current | 14 962 (17.4) | 1273 (16.3) | 13 689 (17.5) | 3.3 |
| Mean (SD) area deprivation index* | 54.4 (19.2) | 55.2 (18.8) | 54.3 (19.3) | 4.7 |
| Long term care | 918 (1.1) | 85 (1.1) | 833 (1.1) | 0.2 |
| Covid-19 vaccination status: | ||||
| None | 14 805 (17.2) | 1107 (14.2) | 13 698 (17.5) | 9.2 |
| 1 vaccine dose | 3193 (3.7) | 242 (3.1) | 2951 (3.8) | 3.7 |
| 2 vaccine doses | 22 125 (25.7) | 1838 (23.5) | 20 287 (26.0) | 5.7 |
| Booster | 45 875 (53.3) | 4631 (59.2) | 41 244 (52.8) | 13.1 |
| Mean (SD) BMI† | 30.8 (5.5) | 30.9 (5.5) | 30.8 (5.4) | 1.4 |
| Mean (SD) eGFR (mL/min/1.73m2)‡ | 77.1 (18.9) | 74.8 (19.1) | 77.3 (18.9) | 13.1 |
| Mean (SD) systolic blood pressure (mm Hg)§ | 134.0 (11.5) | 134.2 (11.5) | 133.9 (11.5) | 2.8 |
| Mean (SD) diastolic blood pressure (mm Hg)§ | 77.9 (7.0) | 77.3 (6.9) | 78 (7.0) | 9.4 |
| History of SARS-CoV-2 infection | 11 987 (13.9) | 1279 (16.4) | 10 708 (13.7) | 7.4 |
| Use of steroid | 6396 (7.4) | 664 (8.5) | 5732 (7.3) | 4.3 |
| Drugs that would have drug-drug interaction with nirmatrelvir-ritonavir: | ||||
| Require an alternative covid-19 treatment to nirmatrelvir-ritonavir | 3959 (4.6) | 751 (9.6) | 3208 (4.1) | 21.9 |
| Require temporary suspension of concomitant drug | 44 088 (51.3) | 4822 (61.7) | 39 266 (50.2) | 23.2 |
| Require adjustment of concomitant drug dosing | 36 666 (42.6) | 4033 (51.6) | 32 633 (41.7) | 19.8 |
| Require monitoring for adverse effects | 34 736 (40.4) | 3869 (49.5) | 30 867 (39.5) | 20.2 |
| Comorbidities: | ||||
| Cancer | 18 145 (21.1) | 1873 (24.0) | 16 272 (20.8) | 7.6 |
| Chronic lung disease | 25 136 (29.2) | 2649 (33.9) | 22 487 (28.8) | 11.1 |
| Dementia | 8783 (10.2) | 923 (11.8) | 7860 (10.1) | 5.6 |
| Diabetes | 35 097 (40.8) | 3521 (45.0) | 31 576 (40.4) | 9.4 |
| Cardiovascular disease | 34 948 (40.6) | 3811 (48.8) | 31 137 (39.8) | 18.0 |
| Hyperlipidemia | 37 288 (43.4) | 3650 (46.7) | 33 638 (43.0) | 7.4 |
| Liver disease | 658 (0.8) | 67 (0.9) | 591 (0.8) | 1.1 |
| Immune dysfunction | 4627 (5.4) | 461 (5.9) | 4166 (5.3) | 2.5 |
| Mean (SD No of hospital admissions¶ | 0.2 (0.8) | 0.3 (0.9) | 0.2 (0.8) | 9.2 |
| Mean (SD) No of outpatient visits¶ | 3.4 (1.4) | 3.6 (1.4) | 3.3 (1.4) | 18.6 |
| Mean (SD) No of blood tests¶ | 9.1 (10.1) | 10.7 (12.1) | 8.9 (9.9) | 16.5 |
| Mean (SD) No of drugs¶ | 12 (7.9) | 13.8 (8.4) | 11.8 (7.8) | 24.9 |
| Mean (SD) No of hospital admissions from Medicare | 0 (0.3) | 0.1 (0.3) | 0 (0.3) | 2.6 |
| Mean (SD) No of outpatient visits from Medicare | 0.2 (0.7) | 0.2 (0.7) | 0.2 (0.7) | 2.6 |
| Influenza vaccine | 62 589 (72.8) | 5993 (76.7) | 56 596 (72.4) | 9.8 |
| Mean (SD) calendar week of SARS-CoV-2 infection in 2022 | 23.7 (9.3) | 26.1 (8.8) | 23.5 (9.3) | 28.2 |
BMI=body mass index; eGFR=estimated glomerular filtration rate; SD=standard deviation; SMD=standardized mean difference.
Measure of socioeconomic disadvantage, ranging from low (0) to high (100).
0.5% of BMI values were missing and were imputed based on age, race, sex, and treatment groups.
2.6% of eGFR values were missing and were imputed based on age, race, sex, and treatment groups.
0.4% of systolic and diastolic blood pressure values were missing and were imputed based on age, race, sex, and treatment groups.
Data collected within one year before study enrollment.